PUBLIC COMPANY
save$REGNREGENERON PHARMACEUTICALS, INC.
$REGN735.20+0.05%Tarrytown, NY, USupdated 16h ago
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
community read0 votes
pipeline
30
marketed
8
phase 3
9
catalysts ytd
8
approvals ytd
3
recalls ytd
0
Pipeline(30)
view full pipeline →pipeline depth30 products
1Preclinical1Phase 14Phase 29Phase 38Marketed4Unknown3pre_registration
Marketed
(atoltivimab + maftivimab + odesivimab)
Ebolavirus Infections (Ebola Hemorrhagic Fever)
MarketedEYLEA HD
wet AMD, diabetic macular edema, retinal vein occlusion
Placenta growth factorVascular endothelial growth factor A, long form
MarketedEylea
Diabetic Macular Edema
Marketedcemiplimab
Melanoma
Programmed cell death protein 1
Marketeddupilumab
Chronic Urticaria
Interleukin-4 receptor subunit alpha
Marketedevinacumab
Homozygous Familial Hypercholesterolemia (HoFH)
Marketedlinvoseltamab
Refractory Multiple Myeloma
Marketedsodium thiosulfate
Hearing Disorders
Phase 3(atisnolerbart + bremzalerbart + umesolerbart)
Birch Pollen Allergy
Phase 3cemdisiran + pozelimab
Myasthenia Gravis
Phase 3fianlimab
Metastatic Melanoma
Lymphocyte activation gene 3 protein
Phase 3freneslerbart + mevonlerbart
Cat Allergy
Upcoming
Recent(90d)
view all catalysts →Active trials
- phase1Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
- phase3A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- —A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
- —An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
- phase4Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
- phase3Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
- phase3A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy
- phase2Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
🐶 Hiring Signal
next earnings Oct 28, 2026
Where REGENERON PHARMACEUTICALS, INC. is staffing up — a leading indicator of pipeline and commercial priorities.
News
- Sanofi pays Regeneron $1B upfront to continue search for Dupixent successorSanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupi…biospace · 2d ago
- STAT+: Sanofi, Regeneron expand partnership after Dupixent successSanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.stat · 3d ago
- The top 12 companies hiring in biopharma nowLooking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.biospace · 3d ago
- FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone diseaseThe approval of Mirum Pharmaceuticals’ ALK2 inhibitor for fibrodysplasia ossificans progressiva on Friday adds a third option for patients who had long been without any treatments, joining Regenero…biospace · 5d ago
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 6d ago
- 9 companies hiring in Pennsylvania nowLooking for a biopharma job in Pennsylvania? Job postings in the state tripled year over year on BioSpace. These nine companies are hiring now.biospace · 11d ago
- Biopharma hiring hotspots: States, disciplines where demand is highestAs biopharma job openings rose this year, opportunities were greatest in Massachusetts and California and in the science/R&D and clinical disciplines, according to BioSpace data. Several other loca…biospace · 17d ago
- Trending: Top biopharma disciplines with jobs live nowFrom engineering to science/R&D, these top seven biopharma disciplines each have hundreds, and in one case over 1,000, positions posted on BioSpace.biospace · 17d ago
- AstraZeneca, Amgen poised to challenge Dupixent’s reign with esophagitis winEven without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for Dupixent in eosinophilic esophagitis.biospace · 1mo ago
- 11 companies hiring in New JerseyLooking for a biopharma job in New Jersey? Job postings in the area have increased year over year, according to BioSpace data. Here are 11 companies with open roles.biospace · 1mo ago
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that